The effects and effectiveness of electromotive drug administration and chemohyperthermia for treating non-muscle invasive bladder cancer

Annals of the Royal College of Surgeons of England

Volumn 96, Issue 6, 2014, Pages 415-419

  Slater, S E ^a   Patel, P ^a,b   Viney, R ^a,b   Foster, M ^b   Porfiri, E ^b   James, N D ^b   Montgomery, B ^c   Bryan, Richard T ^a  

^a UNIVERSITY OF BIRMINGHAM   (United Kingdom)

^b UNIVERSITY HOSPITALS BIRMINGHAM NHS FOUNDATION TRUST   (United Kingdom)

^c FRIMLEY PARK HOSPITAL NHS FOUNDATION TRUST   (United Kingdom)

Author keywords

Chemohyperthermia; Electromotive drug administration; Urothelial cancer

Indexed keywords

ANTINEOPLASTIC AGENT;

ELECTROCHEMOTHERAPY; HUMAN; HYPERTHERMIC THERAPY; INTRAVESICAL DRUG ADMINISTRATION; MULTIMODALITY CANCER THERAPY; PATHOLOGY; PROCEDURES; TUMOR INVASION; URINARY BLADDER NEOPLASMS;

ADMINISTRATION, INTRAVESICAL; ANTINEOPLASTIC AGENTS; COMBINED MODALITY THERAPY; ELECTROCHEMOTHERAPY; HUMANS; HYPERTHERMIA, INDUCED; NEOPLASM INVASIVENESS; URINARY BLADDER NEOPLASMS;

EID: 84907147920     PISSN: 00358843     EISSN: None     Source Type: Journal    
DOI: 10.1308/003588414X13946184901001     Document Type: Review

References (35)

1. Burger M, Catto JW, Dalbagni G et al. Epidemiology and risk factors of urothelial bladder cancer. Eur Urol 2013; 63: 234-241.
2. Ploeg M, Aben KK, Kiemeney LA. The present and future burden of urinary bladder cancer in the world. World J Urol 2009; 27: 289-293.
3. van Rhijn BW, Burger M, Lotan Y et al. Recurrence and progression of disease in non-muscle-invasive bladder cancer: from epidemiology to treatment strategy. Eur Urol 2009; 56: 430-442.
4. Kaufman DS, Shipley WU, Feldman AS. Bladder cancer. Lancet 2009; 374: 239-249.
5. Lorusso V, Silvestris N. Systemic chemotherapy for patients with advanced and metastatic bladder cancer: current status and future directions. Ann Oncol 2005; 16: 485-489.
6. Wallace DM, Bryan RT, Dunn JA et al. Delay and survival in bladder cancer. BJU Int 2002; 89: 868-878.
7. James ND, Hussain SA, Hall E et al. Radiotherapy with or without chemotherapy in muscle-invasive bladder cancer. N Engl J Med 2012; 366: 1,477-1,488.
8. Neoadjuvant chemotherapy in invasive bladder cancer: update of a systematic review and meta-analysis of individual patient data. Eur Urol 2005; 48: 202-205.
9. Bryan RT, Collins SI, Daykin MC et al. Mechanisms of recurrence of Ta/T1 bladder cancer. Ann R Coll Surg Engl 2010; 92: 519-524.
10. Konda´s J, Kiss L, Hata´r A et al. The effect of intravesical mitomycin C on the recurrence of superficial (Ta-T1) bladder cancer. A Hungarian multicenter study. Int Urol Nephrol 1999; 31: 451-456.
11. Brausi M. Are new technologies for detection and treatment of non-muscleinvasive bladder cancer (NMIBC) so important? A plea for adoption by teaching programs to improve results after standard white light transurethral resection of NMIBC. Eur Urol 2012; 61: 914-916.
12. Bryan RT. Optimising existing therapeutic strategies for the treatment of nonmuscle-invasive bladder cancer: the role of intensive neoadjuvant intravesical mitomycin C. Eur Urol 2012; 62: 803-805.
13. Logan C, Brown M, Hayne D. Intravesical therapies for bladder cancer -indications and limitations. BJU Int 2012; 110 Suppl 4: 12-21.
14. Giannantoni A, Di Stasi SM, Chancellor MB et al. New frontiers in intravesical therapies and drug delivery. Eur Urol 2006; 50: 1,183-1,193.
15. Di Stasi SM, Giannantoni A, Giurioli A et al. Sequential BCG and electromotive mitomycin versus BCG alone for high-risk superficial bladder cancer: a randomised controlled trial. Lancet Oncol 2006; 7: 43-51.
16. Di Stasi SM, Vespasiani G, Giannantoni A et al. Electromotive delivery of mitomycin C into human bladder wall. Cancer Res 1997; 57: 875-880.
17. Di Stasi SM, Giannantoni A, Massoud R et al. Electromotive versus passive diffusion of mitomycin C into human bladder wall: concentration-depth profiles studies. Cancer Res 1999; 59: 4,912-4,918.
18. Schmittgen TD, Wientjes MG, Badalament RA, Au JL. Pharmacodynamics of mitomycin C in cultured human bladder tumors. Cancer Res 1991; 51: 3,849-3,856.
19. Hicks RM, Ketterer B, Warren RC. The ultrastructure and chemistry of the luminal plasma membrane of the mammalian urinary bladder: a structure with low permeability to water and ions. Philos Trans R Soc Lond B Biol Sci 1974; 268: 23-38.
20. Yates DR, Brausi MA, Catto JW et al. Treatment options available for bacillus Calmette-Gue´rin failure in non-muscle-invasive bladder cancer. Eur Urol 2012; 62: 1,088-1,096.
21. Di Stasi SM, Valenti M, Verri C et al. Electromotive instillation of mitomycin immediately before transurethral resection for patients with primary urothelial non-muscle invasive bladder cancer: a randomised controlled trial. Lancet Oncol 2011; 12: 871-879.
22. Lammers RJ, Witjes JA, Inman BA et al. The role of a combined regimen with intravesical chemotherapy and hyperthermia in the management of non-muscleinvasive bladder cancer: a systematic review. Eur Urol 2011; 60: 81-93.
23. van der Heijden AG, Kiemeney LA, Gofrit ON et al. Preliminary European results of local microwave hyperthermia and chemotherapy treatment in intermediate or high risk superficial transitional cell carcinoma of the bladder. Eur Urol 2004; 46: 65-71.
24. Webb H, Lubner MG, Hinshaw JL. Thermal ablation. Semin Roentgenol 2011; 46: 133-141.
25. Rampersaud EN, Vujaskovic Z, Inman BA. Hyperthermia as a treatment for bladder cancer. Oncology 2010; 24: 1,149-1,155.
26. Song CW. Effect of local hyperthermia on blood flow and microenvironment: a review. Cancer Res 1984; 44: 4721s-4730s.
27. Roca C, Primo L, Valdembri D et al. Hyperthermia inhibits angiogenesis by a plasminogen activator inhibitor 1-dependent mechanism. Cancer Res 2003; 63: 1,500-1,507.
28. Peer AJ, Grimm MJ, Zynda ER, Repasky EA. Diverse immune mechanisms may contribute to the survival benefit seen in cancer patients receiving hyperthermia. Immunol Res 2010; 46: 137-154.
29. Baronzio G, Gramaglia A, Fiorentini G. Hyperthermia and immunity. A brief overview. In Vivo 2006; 20: 689-695.
30. Van Der Heijden AG, Jansen CF, Verhaegh G et al. The effect of hyperthermia on mitomycin-C induced cytotoxicity in four human bladder cancer cell lines. Eur Urol 2004; 46: 670-674.
31. Moskovitz B, Halachmi S, Moskovitz M et al. 10-year single-center experience of combined intravesical chemohyperthermia for nonmuscle invasive bladder cancer. Future Oncol 2012; 8: 1,041-1,049.
32. Bryan RT and James ND. Bladder Cancer: Time for a Rethink? Oncology (Williston Park) 2011: 25: 965-8.
33. Bryan RT, Kirby R, O'Brien T, Mostafid H. So much cost, such little progress. Eur Urol 2014 (in print).
34. Brausi M, Campo B, Pizzocaro G et al. Intravesical electromotive administration of drugs for treatment of superficial bladder cancer: a comparative phase II study. Urology 1998; 51: 506-509.
35. Di Stasi SM, Giannantoni A, Stephen RL et al. Intravesical electromotive mitomycin C versus passive transport mitomycin C for high risk superficial bladder cancer: a prospective randomized study. J Urol 2003; 170: 777-782.